Mirae Asset Global Investments
ATXS

Mirae Asset Global Investments’s Astria Therapeutics ATXS Stock Holding History

Mirae Asset Global Investments’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,182
Closed -$15.9K – 1651
2025
Q3 		$15.9K Buy
2,182
+2
+0.1% +$14 ﹤0.01% 1521
2025
Q2 		$11.7K Buy
2,180
+274
+14% +$1.33K ﹤0.01% 1471
2025
Q1 		$10.9K Buy
1,906
+25
+1% +$175 ﹤0.01% 1458
2024
Q4 		$17.2K Buy
+1,881
New +$20K ﹤0.01% 1439
2024
Q1 		– Sell
-13,495
Closed -$104K – 2453
2023
Q4 		$104K Hold
13,495
– – ﹤0.01% 2462
2023
Q3 		$101K Hold
13,495
– – ﹤0.01% 2457
2023
Q2 		$112K Buy
+13,495
New +$156K ﹤0.01% 2478

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mirae Asset Global Investments's ATXS Position: Q4 2025 in Review

Mirae Asset Global Investments sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 2,182 shares — an estimated $15.9K sold.

Mirae Asset Global Investments first reported a position in ATXS in Q2 2023 and held it in 7 quarters. The position peaked at $112K in Q2 2023. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

  • Mirae Asset Global Investments reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Mirae Asset Global Investments sold 2,182 Astria Therapeutics shares in Q4 2025, an estimated $15.9K.
  • Mirae Asset Global Investments first reported a position in Astria Therapeutics in Q2 2023 and held it in 7 quarters.
  • Mirae Asset Global Investments's Astria Therapeutics position peaked at $112K in Q2 2023.
  • 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on Mirae Asset Global Investments's 13F filing for Q4 2025, filed 26 Jan 2026.